26 April 2021 - Informed by expert input from patient groups, former regulators, payers, and life science companies, white paper analyses ...
16 April 2021 - For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both ...
13 April 2021 - ISPOR announced today the publication of new guidance on how to evaluate the quality and risk ...
12 April 2021 - Many countries use international (or external) reference pricing—benchmarking prices against those in other countries—to manage spending ...
12 April 2021 - Final assessment to be published on 16 November; through 10 May, ICER is accepting public Input ...
12 April 2021 - New ICER pilot will incorporate more than 24 months of observational real world demographic, utilisation, and cost ...
8 April 2021 - Report will be subject of CTAF meeting in October 2021; draft scoping document open to public comment ...
5 April 2021 - The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially ...
17 March 2021 - A commonly-used analysis to determine a medicine's value is based on flawed methodologies that would diminish ...
15 March 2021 -Aurinia Pharmaceuticals today announced a favorable assessment regarding the cost-effectiveness and value of Lupkynis (voclosporin), based on ...
15 March 2021 - Report will be subject of New England CEPAC meeting in September 2021; draft scoping document open ...
12 March 2021 - The evidence suggests belimumab and voclosporin represent important new treatment options for lupus nephritis; there is ...
9 March 2021 - The rapid spread of the current COVID-19 pandemic has affected societies worldwide, leading to excess mortality, long ...
5 March 2021 - Independent appraisal committee determines the evidence is not adequate to demonstrate that roxadustat provides a net ...
2 March 2021 - The U.S. has never had a publicly funded, independent health technology assessment organisation to evaluate prescription drugs, ...